Biomedical Science and Research
by Jenna Ogilvie | Feb 11, 2016 | Commentary, Perspectives
Unlike with most food additives, the safety evaluation of macronutrients poses a challenge to risk assessors because of their inherent nutritional value and relatively large dietary exposure. A safety assessment model of macronutrients based solely on...
by Jenna Ogilvie | Feb 2, 2016 | Commentary, Perspectives
In early 2015, President Obama announced a $215 million investment in the 2016 budget to revolutionize health improvement efforts and disease treatment. The Precision Medicine Initiative (PMI) is a new model of patient-powered research using big data to...
by Laura DeStefano | Sep 11, 2015 | Discussion Paper, Perspectives
Abstract Despite the fact that they have gone through a rigorous approval process, uncertainty about newly approved drugs always exists. The uncertainty is amplified when drugs are approved on preliminary or interim evidence (i.e., accelerated approval) or on...
by Laura DeStefano | Jun 23, 2015 | Discussion Paper, Perspectives
ABSTRACT Background: Despite greater spending on health care and biomedical research, the United States has poorer health outcomes than competitive nations. Information is needed on the potential impact of interventions to better guide resources allocation. Objective:...
by Jenna Ogilvie | Jun 22, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Feb 26, 2015 | Commentary, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Feb 19, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Feb 12, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Feb 5, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Jan 29, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
Page 6 of 8« First«...45678»
